Avedro Becomes Exclusive Global Supplier of MedioCROSS®Riboflavin for Corneal Cross-Linking

Avedro Becomes Exclusive Global Supplier of MedioCROSS®Riboflavin for Corneal Cross-Linking

June 12, 2014

Avedro’s VibeX® and MedioCROSS Are Two of the World’s Leading Ophthalmic Riboflavin Product Brands

Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration

Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration

June 13, 2014

Major Milestone in Landmark Collaboration Between Agios and Celgene

Moderna Announces Expansion to New Facility in Kendall Square

Moderna Announces Expansion to New Facility in Kendall Square

June 12, 2014

Company Doubles Footprint in Cambridge Due to Rapid Growth

Kevin Hrusovsky Joins Quanterix as Executive Chairman

Kevin Hrusovsky Joins Quanterix as Executive Chairman

June 10, 2014

LEXINGTON, Mass., Jun 10, 2014 (BUSINESS WIRE) -- Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Kevin Hrusovsky as Executive Chairman of its Board of Directo

Syros Pharmaceuticals Appoints Genomics Entrepreneur Jorge Conde to Dual Role as Chief Financial Officer and Chief Product Officer

Syros Pharmaceuticals Appoints Genomics Entrepreneur Jorge Conde to Dual Role as Chief Financial Officer and Chief Product Officer

June 10, 2014

WATERTOWN, Mass.--()--Syros Pharmaceuticals

Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis

Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis

June 9, 2014

– Study met primary efficacy endpoint with statistical significance after 24 weeks of treatment –

– Safety data are supportive of differentiated product profile –

–   Investor conference call and webcast today at 5:00 p.m. EDT (2:00 p.m. PDT) –

Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia

Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia

June 9, 2014

 Initial Safety and Pharmacokinetic Findings From Single Ascending Dose Trial Support Early Advancement

Seres Health Closes Series B Financing and Enters into a Research Agreement with Mayo Clinic

Seres Health Closes Series B Financing and Enters into a Research Agreement with Mayo Clinic

June 9, 2014

CAMBRIDGE, Mass., June 9, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, announced today that it has closed its $10 million Series B financing that included existing investors Flagship Ventures and Enso Ventures, and included new investors, Mayo Clinic, Alexandria Venture Investments, and several private investors. The company has also entered into an exclusive research collaboration with the Mayo Clinic.

Flagship Ventures Commences Its Sixth VentureLabs™ Fellowship Program Focused On Entrepreneurial Innovation

Flagship Ventures Commences Its Sixth VentureLabs™ Fellowship Program Focused On Entrepreneurial Innovation

June 5, 2014

CAMBRIDGE, Mass., June 5, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, announced the start of its sixth VentureLabs™ Fellowship Program, a unique opportunity for top graduate and post-graduate students to learn VentureLabs' approach to company conception, innovation and entrepreneuring.

T2 Biosystems Submits 510(k) Application to the FDA for Review of T2Dx and T2Candida

T2 Biosystems Submits 510(k) Application to the FDA for Review of T2Dx and T2Candida

June 3, 2014

LEXINGTON, Mass.--()--T2 Biosystems today announced that it has filed a 510(k) premarket submission for T2Dx and T2Candida with the U.S. Food and Drug Administration (FDA).